ABSTRACT
Objective To discuss the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in adenomyosis and its clinical significance. Methods The expression of COX-2 and VEGF was examined by immunohistochemistry SP method, in ectopic endometrium and eutopic endometrium, compared with normal endometrium. Results (1) COX-2 expression in ectopic, eutopic endometrium with adenomyosis was significantly higher than that in control group (P<0.05). No statistically significant difference was found between ectopic endometrium and eutopic endometrium group with adenomyosis (P0.05).(2) VEGF expressions in ectopic, eutopic endometrium with adenomyosis were both significantly higher than that of control group (P<0.05); no statistically significant difference was found between ectopic endometrium and eutopic endometrium group (P0.05).(3) COX-2 and VEGF had the positive relativity in the ectopic endometriumal expression of adenomyosis patient (P<0.05). Conclusion COX-2 and VEGF may play a key role in adenomyosis. Both may have close relation in angiogenesis and may provide new targets for therapy of adenomyosis.
ABSTRACT
AIM In order to search inhibitors of protein kinase CK2, we observed the inhibitory effects of kaempferol on recombinant human protein kinase CK2 holoenzyme and its kinetics in vitro. METHODSCloning, prokaryotic expression and purification of human protein kinase CK2 α' and β subunits by gene engineering, the two subunits were mixed at equal molar ratio to reconstitute CK2 holoenzyme and identify its biological properties. The CK2 activity was assayed by detecting incorporation of 32P of [γ-32P]ATP into the substrate. The inhibitory effect of kaempferol on CK2 was assayed in the presence of different concentrations of kaempferol. Kinetic analysis of kaempferol-induced inhibition was carried out in the condition that casein concentration was fixed at 2 g·L-1 and ATP was changed at various concentrations(10, 20, 40, 80 μmol·L-1), or ATP was fixed at 10 μmol·L-1 and casein was changed at different concentrations (1, 2, 4, 8 g·L-1). RESULTS Kaempferol was shown to strongly inhibit the holoenzyme activity of recombinant human protein kinase CK2 with IC50 of 1.9 μmol·L-1, which was more effective than chrysin, morin and genistein which are both known as CK2 special inhibitors. Kinetic studies of kaempferol on recombinant human CK2 showed that kaempferol acted as a noncompetitive inhibitor with substrate ATP(Ki=1.1 μmol·L-1) and casein (Ki=3.1 μmol·L-1). CONCLUSIONKaempferol is a novel potent inhibitor of protein kinase CK2 in vitro. Discussions indicate that flavonoid inhibitors of CK2 may adopt different orientations in theactive site of CK2 and that these are determined by the number and position of their hydroxyl groups.
ABSTRACT
Objective To study the hygroscopicity of glucosamine sulfate powder.Methods Hygroscopic studies were conducted on glucosamine sulfate powder at 5℃ and 30℃ used gravimetric method,determined the equilibrium moisture content(EMC) and drew the moisture sorption isotherms.The experimental values were regressed using the BET model,calculated the monolayer moisture content.Results At 30℃,when water activity exceeded 0.43,samples agglomerated,browned and lose adsorbed water,EMC declined;At 5℃,the isotherm had typical ob-S shape,the EMC increased with water activity raising.At 30℃ and 5℃,the monolayer moisture content were 4.8633,5.5740g/100g respectively.Conclusion At 5,30℃ the appropriate aw for storage appeared to be below 0.3056,0.2784,respectively.
ABSTRACT
Objective To study the stability of glucosamine sulfate prepared by spray drying. Methods The microcapsules of glucosamine sulfate were produced by spray drying,and the effects of different adjuvants on the indices of the microcapsules,such as the yield,fluidity,glass transition temperature and store stability were compared. Results and conclusion The yield,fluidity,glass transition temperature and stability of glucosamine sulfate could be greatly improved by adding 0.5%,1.0%,2.0%,3.0% and 5.0% cyclodextrin,gelatin and copvidone.